# Kisspeptin FAQ: Isoforms, Half-Life, Testosterone and Fertility, Answered

> Kisspeptin questions answered from the literature — the isoform difference, half-life, receptor desensitization, testosterone, fertility and IVF triggering, each answer cited.

The isoform difference, the half-lives, the testosterone and fertility data, and the desensitization problem — each answer direct and cited.

## What is the difference between kisspeptin-10 and kisspeptin-54?

Length and duration. Kisspeptin-10 is the ten-residue fragment (about `1302.5 Da`, ~`4-minute` half-life); kisspeptin-54 is the fifty-four-residue isoform (about `5857 Da`, ~`27.6-minute` half-life) [8]. Both end in the same receptor-binding tail and point the same direction — at matched infusion rates in men they give comparable acute gonadotropin responses — so the practical difference is that KP-54 sustains its signal far longer [9].

## What is the half-life of kisspeptin?

It depends on the isoform. Kisspeptin-54 has a measured human plasma half-life of `27.6 ± 1.1 minutes` [8], while kisspeptin-10 lasts only about `4 minutes` because plasma peptidases clear the short fragment quickly [3]. The larger KP-54 resists enzymatic cleavage better, which is why it reaches higher peaks and acts longer than KP-10 at equal doses [11].

## Why does kisspeptin-54 produce longer-lasting LH release than kisspeptin-10?

Because it survives longer in the blood. Mechanistic work attributes KP-54's higher peak levels and more sustained LH release directly to its greater resistance to peptidase cleavage, and reports it also activates central GnRH neurons more effectively [11]. The intact fifty-four-residue peptide is degraded more slowly than the ten-residue fragment, so its signal persists — a `27.6-minute` half-life versus about `4 minutes` [8].

## Does repeated kisspeptin dosing cause desensitization of the GPR54 receptor?

Yes — this is the defining limitation. Twice-daily subcutaneous kisspeptin-54 in women with hypothalamic amenorrhea caused the acute LH response to fall from about `24 IU/L` on day 1 to roughly `2.5 IU/L` by the fourteenth injection day [10]. High-dose continuous IV infusion likewise desensitized the axis during the infusion [4]. Sustained or frequent KISS1R activation downregulates the receptor, so continuous dosing tends to defeat itself.

## What is the plasma half-life of kisspeptin-10 compared to kisspeptin-54?

Kisspeptin-10 clears in roughly `4 minutes`; kisspeptin-54 lasts about `27.6 ± 1.1 minutes` — close to a sevenfold difference [3][8]. The gap reflects size and enzymatic stability: the short fragment is rapidly cut by plasma peptidases, while the larger peptide resists cleavage and sustains its action far longer [11].

## What is kisspeptin?

Kisspeptin is the KISS1-gene neuropeptide that sits at the top of the reproductive hormone axis — a KISS1R (GPR54) agonist that stimulates hypothalamic GnRH neurons, which in turn drive LH and FSH and the sex steroids [1]. The proof of its importance is genetic: people with loss-of-function GPR54 mutations fail to enter puberty, and knockout mice reproduce that phenotype [1]. It is not a sex hormone itself — it is the upstream switch.

## What does kisspeptin do?

It wakes the reproductive axis. Kisspeptin binds KISS1R on GnRH neurons and depolarizes them — raising firing rate by about `87 ± 4%` in adult GnRH neurons in one study — which triggers pulsatile GnRH release, then LH and FSH from the pituitary, then the gonadal sex steroids [2]. It is the master upstream signal; without working kisspeptin–GPR54 signaling, puberty does not start [1].

## Does kisspeptin increase testosterone?

In studies of healthy men, yes — indirectly, by raising LH. Intravenous kisspeptin-10 at a higher `4 µg/kg/h` infusion raised serum testosterone from `16.6` to `24.0 nmol/L`, downstream of its LH stimulation [3]. Kisspeptin does not supply testosterone; it drives the LH signal that tells the testes to make it. This is research data in a supervised setting, not a dosing recommendation.

## How much does kisspeptin increase testosterone?

One study in healthy men reported serum testosterone rising from `16.6` to `24.0 nmol/L` under a continuous IV kisspeptin-10 infusion at `4 µg/kg/h` — about a 45% increase from baseline [3]. The same study's lower doses primarily raised LH and pulse frequency; the testosterone rise followed the stronger LH stimulation [3]. These are research figures, attributed to a defined population and route, not a personal target.

## What is kisspeptin used for in research?

It is studied as a probe and a potential tool for the reproductive axis. A 2025 systematic review mapped 29 interventional trials across secondary amenorrhea, regulation of puberty onset, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation [7]. The genetics that opened the field showed kisspeptin–GPR54 signaling is essential for reproductive maturation [1]. No use is regulatory-approved.

## Can kisspeptin help with fertility?

In research, it has shown clear fertility-relevant effects. A Phase 2 trial used subcutaneous kisspeptin-54 (`3.2–12.8 nmol/kg`) to trigger oocyte maturation in 95% of high-OHSS-risk IVF patients with no case of moderate-to-critical OHSS, and a `9.6 nmol/kg` dose gave the highest live-birth rate (62%) [5]. It remains investigational and is not an approved fertility treatment.

## Can kisspeptin restore ovulation in women with hypothalamic amenorrhea?

In supervised studies it restored the LH pulsatility that ovulation depends on. Continuous IV kisspeptin-54 (`0.01–1.00 nmol/kg/h`) raised LH pulses from `1.6` to `5.0` per 8 hours (about threefold) and pulse secretory mass roughly sixfold versus vehicle in women with hypothalamic amenorrhea, though the highest dose caused tachyphylaxis [4]. This is investigational research, not an approved therapy.

## What is the KISS1 gene?

KISS1 (on chromosome 1q32) is the gene that encodes the kisspeptin family. It was discovered in 1996 as a metastasis-suppressor gene, and its product was only later recognized as the upstream activator of GnRH neurons [1]. Loss-of-function mutations in its receptor, GPR54 (KISS1R), cause failure of puberty — the finding that established the gene's role in reproduction [1].

## What is metastin and how does it relate to kisspeptin?

Metastin is the original name for kisspeptin-54. When KISS1 was identified as a metastasis-suppressor gene, its fifty-four-residue product was named *metastin*; the same molecule is now usually called kisspeptin-54 [1]. So metastin and KP-54 are interchangeable names for the longer isoform — the one with the `~28-minute` half-life used in most clinical studies [8].

## How was kisspeptin discovered?

Twice over, in effect. KISS1 was first found in 1996 as a metastasis-suppressor gene in human melanoma. Its true reproductive role emerged in 2003, when loss-of-function mutations in the receptor GPR54 were shown to cause hypogonadotropic hypogonadism and failure of puberty in humans, with knockout mice confirming it — recasting kisspeptin as the master upstream switch of the reproductive axis [1].

## What receptor does kisspeptin bind?

Kisspeptin binds KISS1R, a Gq/11-coupled G-protein-coupled receptor formerly known as the orphan GPR54 (also hOT7T175 / AXOR12) [1]. The receptor is expressed on hypothalamic GnRH neurons; activating it fires the phospholipase-C / IP3 / calcium cascade that depolarizes the neuron and drives GnRH release [2]. Its essential role was proven by the puberty failure that follows loss-of-function GPR54 mutations [1].

## How does kisspeptin work in the body?

It works from the top of the chain. Kisspeptin binds KISS1R on GnRH neurons and depolarizes them through a PLC / IP3 / intracellular-calcium cascade that closes potassium channels and opens cation channels [2]. That triggers pulsatile GnRH release, which drives LH and FSH from the pituitary, which drive the gonadal sex steroids [1]. KNDy neurons in the arcuate nucleus are thought to pace the underlying pulse [2].

## How long does kisspeptin take to work?

Fast — minutes. In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at 30 minutes, lifting LH from `4.1` to `12.4 IU/L` [3]. The 2025 intranasal kisspeptin-54 study likewise described *rapid* LH stimulation after dosing [6]. The hormonal response is quick; how long it lasts depends on the isoform's half-life — roughly `4 minutes` for KP-10 versus `~28 minutes` for KP-54 [8].

## What is the mechanism by which kisspeptin-10 exerts its effects?

Kisspeptin-10 binds KISS1R on GnRH neurons and activates a phospholipase-C / IP3 / intracellular-calcium cascade; that closes potassium channels and opens non-selective cation channels, depolarizing the neuron — in one study raising firing rate by about `87 ± 4%` — and driving pulsatile GnRH release [2]. The ten-residue fragment keeps the Arg-Phe-amide tail the receptor needs, so it retains full activity despite its small size [3].

## How does stress suppress kisspeptin and disrupt the reproductive axis?

Through the same KNDy circuitry that normally drives it. A review of functional hypothalamic amenorrhea describes how psychological stress, disordered eating, low body weight and excessive exercise suppress GnRH pulsatility and lower LH and estradiol, with KNDy (kisspeptin / neurokinin B / dynorphin) neurons acting on GnRH neurons as central to this regulation [14]. When the kisspeptin signal quiets, the axis downstream of it quiets too — which is why restoring LH pulses with kisspeptin-54 has been studied in exactly this population [4].

## How does kisspeptin reduce OHSS risk compared to hCG as an IVF trigger?

By triggering a more physiological, self-limiting hormone surge instead of a long-lasting one. In a Phase 2 trial of 60 high-OHSS-risk women, a subcutaneous kisspeptin-54 trigger (`3.2–12.8 nmol/kg`) matured oocytes in 95% of women **with no case of moderate, severe or critical OHSS** [5]. The trial framed kisspeptin-54 as a safer alternative trigger because it stimulates the body's own gonadotropin release rather than supplying a sustained external signal [5].

## Can kisspeptin-54 trigger ovulation more safely than GnRH agonists in IVF?

The Phase 2 evidence points that way on safety. Subcutaneous kisspeptin-54 (`3.2–12.8 nmol/kg`) triggered oocyte maturation in 95% of high-risk women with no moderate-to-critical OHSS, and the `9.6 nmol/kg` dose produced the highest live-birth rate (62%) [5]. Because kisspeptin acts one step upstream — driving the body's own GnRH and gonadotropin release — it was studied specifically as a gentler trigger; it remains investigational [5].

---

A noir reading of the Kisspeptin record — one upstream signal traced from KISS1 to GnRH and logged where the trials confirm it, the brief KP-10 flare set apart from the longer KP-54 burn, the fading-with-overuse and not-approved, not-a-supplement truths held in the light; no clinic behind the pulse, and nothing here dosed, dispensed, or sold.